Compare Stocks

→ Conflict In Israel Sends Gold Soaring ???? Here’s How To Get Your Share (From Colonial Metals) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTC Benitec Biopharma	$9.25 +0.8%	$6.05	$1.86 ▼ $10.29	$23.98M	0.8	63,824 shs	33,403 shs
ETST Earth Science Tech	$0.15 +25.0%	$0.07	$0.00 ▼ $0.16	$46.50M	1.64	119,337 shs	244,860 shs
PHIO Phio Pharmaceuticals	$0.70 -9.0%	$0.78	$0.50 ▼ $6.85	$3.24M	1.36	343,149 shs	53,455 shs
XBIO Xenetic Biosciences	$3.90 -3.5%	$4.12	$2.55 ▼ $5.97	$6.01M	2.56	5,566 shs	3,379 shs

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTC Benitec Biopharma	+6.25%	+3.49%	+55.56%	+222.11%	+134.99%
ETST Earth Science Tech	+9.09%	+20.00%	+109.79%	+84.62%	+200.75%
PHIO Phio Pharmaceuticals	-3.34%	-0.73%	+13.24%	+30.84%	-80.99%
XBIO Xenetic Biosciences	+2.97%	+3.63%	-14.37%	+4.71%	+0.54%

Biggest hedge fund manager has huge warning for U.S. dollar (Ad)

Prescient CEO Makes Shocking New Prediction Known for his eerily accurate market calls over the years, this CEO has just revealed his newest prediction about "America's New Money."

Get the details before it's taken offline.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTC Benitec Biopharma	1.847 of 5 stars	3.5	2.0	0.0	0.0	3.8	0.8	0.0
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	1.8844 of 5 stars	3.5	3.0	0.0	0.0	0.0	2.5	0.6
XBIO Xenetic Biosciences	0.1301 of 5 stars	0.0	3.0	0.0	0.0	0.6	0.0	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTC Benitec Biopharma	3.00	Buy	$16.00	72.97% Upside
ETST Earth Science Tech	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	3.00	Buy	$4.00	467.78% Upside
XBIO Xenetic Biosciences	2.00	Hold	N/A	N/A

Current Analyst Ratings

Latest PHIO, BNTC, ETST, and XBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
4/22/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$10.00 ➝ $16.00
2/15/2024	BNTC Benitec Biopharma	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$8.00 ➝ $10.00

(Data available from 5/10/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTC Benitec Biopharma	$61K	393.05	N/A	N/A	$0.12 per share	77.08
ETST Earth Science Tech	$50K	929.95	N/A	N/A	N/A	∞
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$2.06 per share	N/A
XBIO Xenetic Biosciences	$2.54M	2.37	N/A	N/A	$6.36 per share	0.61

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTC Benitec Biopharma	-$19.56M	-$1.75	N/A	∞	N/A	N/A	-204.34%	-142.81%	5/20/2024 (Estimated)
ETST Earth Science Tech	-$370K	N/A	0.00	∞	N/A	5.77%	20.61%	11.73%	N/A
PHIO Phio Pharmaceuticals	-$10.83M	-$5.93	N/A	∞	N/A	N/A	-134.66%	-105.86%	8/8/2024 (Estimated)
XBIO Xenetic Biosciences	-$4.14M	-$2.75	N/A	N/A	N/A	-162.84%	-36.43%	-33.74%	8/9/2024 (Estimated)

Latest PHIO, BNTC, ETST, and XBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/1/2024	Q4 2023	PHIO Phio Pharmaceuticals	N/A	-$0.17	-$0.17	-$0.17	N/A	N/A
3/21/2024	Q4 2023	XBIO Xenetic Biosciences	-$0.87	-$0.77	+$0.10	-$0.77	$0.68 million	$0.67 million
2/13/2024	Q2 2024	BNTC Benitec Biopharma	N/A	-$2.64	-$2.64	-$2.64	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTC Benitec Biopharma	N/A	N/A	N/A	N/A	N/A
ETST Earth Science Tech	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTC Benitec Biopharma	0.01	3.62	3.62
ETST Earth Science Tech	0.10	0.87	0.39
PHIO Phio Pharmaceuticals	N/A	5.70	5.71
XBIO Xenetic Biosciences	N/A	11.84	11.84

Ownership

Institutional Ownership

Company	Institutional Ownership
BNTC Benitec Biopharma	52.19%
ETST Earth Science Tech	N/A
PHIO Phio Pharmaceuticals	57.31%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
BNTC Benitec Biopharma	4.30%
ETST Earth Science Tech	24.90%
PHIO Phio Pharmaceuticals	0.77%
XBIO Xenetic Biosciences	9.00%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTC Benitec Biopharma	16	2.59 million	2.48 million	No Data
ETST Earth Science Tech	8	309.98 million	232.80 million	Not Optionable
PHIO Phio Pharmaceuticals	8	4.59 million	4.56 million	Not Optionable
XBIO Xenetic Biosciences	4	1.54 million	1.40 million	Not Optionable

PHIO, BNTC, ETST, and XBIO Headlines

Source	Headline
	Xenetic Biosciences (XBIO) Reports Q1 Loss, Misses Revenue Estimates zacks.com - May 9 at 9:00 PM
	Xenetic Biosciences Inc (XBIO) investing.com - April 10 at 3:28 PM
	Xenetic Biosciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag finance.yahoo.com - March 24 at 5:09 PM
	Xenetic Dips on Full-Year Results baystreet.ca - March 22 at 7:33 PM
	Xenetic Biosciences reports FY results msn.com - March 22 at 8:51 AM
	Xenetic Biosciences, Inc. Reports Full Year 2023 Financial Results accesswire.com - March 22 at 8:00 AM
	Xenetic to advance DNase programme with UVA partnership msn.com - January 18 at 1:37 PM
	Xenetic Biosciences Inc XBIO morningstar.com - January 4 at 5:10 PM
	Xenetic Biosciences Stock (NASDAQ:XBIO), Guidance and Forecast benzinga.com - December 11 at 9:01 AM
	Most Shareholders Will Probably Agree With Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation finance.yahoo.com - November 30 at 10:39 AM
	Xenetic Biosciences: Q3 Earnings Insights benzinga.com - November 10 at 3:38 PM
	MediciNova: Q3 Earnings Snapshot washingtonpost.com - November 10 at 10:37 AM
	Xenetic Biosciences, Inc. to Participate at the Virtual Investor Ask the CEO Conference finance.yahoo.com - October 11 at 9:30 AM
	Xenetic Biosciences (XBIO) Upgraded to Strong Buy: What Does It Mean for the Stock? msn.com - July 13 at 1:44 PM
	Xenetic Biosciences, Inc. Reports First Quarter 2023 Financial Results and Provides Business Update finance.yahoo.com - May 11 at 5:06 PM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison \| Morningstar morningstar.com - May 5 at 10:21 AM
	Xenetic Biosciences, Inc. Bolsters R&D and Regulatory Expertise with Appointment of Reid P. Bissonnette, Ph.D. as Executive Consultant for Translational Research and Development finance.yahoo.com - May 4 at 10:02 AM
	Xenetic Biosciences, Inc. Adds Business Development Expertise with Appointment of Scott N. Cullison finance.yahoo.com - May 3 at 10:26 AM
	HC Wainwright & Co. Reiterates Xenetic Biosciences (XBIO) Buy Recommendation msn.com - April 12 at 10:37 PM
	Xenetic Biosciences forms research collaboration with TSRI pharmaceutical-technology.com - April 12 at 12:36 PM
	Analysts Offer Insights on Healthcare Companies: Adaptimmune Therapeutics (ADAP) and Xenetic Biosciences (XBIO) markets.businessinsider.com - April 12 at 2:30 AM
	Xenetic Biosciences, Inc. Announces Research and Development Collaboration with The Scripps Research Institute to Advance DNase Platform finance.yahoo.com - April 11 at 8:43 AM
	JTC Team, LLC: JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finanznachrichten.de - March 16 at 12:09 PM
	JTC Team to Host Virtual Investor NETs in Cancer Spotlight Event Featuring Xenetic Biosciences finance.yahoo.com - March 16 at 12:09 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Benitec Biopharma

NASDAQ:BNTC

Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.

Earth Science Tech

OTCMKTS:ETST

Earth Science Tech, Inc. focuses on health and wellness industry. It operates men's health telemedicine platform under brand Peak name; and operates pharmacy. The company offers supplements and topicals products. The company was formerly known as Ultimate Novelty Sports, Inc. and changed its name to Earth Science Tech, Inc. in March 2014. Earth Science Tech, Inc. was incorporated in 2010 and is headquartered in Miami, Florida.

Phio Pharmaceuticals

NASDAQ:PHIO

Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. The company develops PH-762, INTASYL compound which reduces the expression of cell death Protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; PH-894 that silences the BRD4, a protein which controls gene expression in both T cells and tumor cells, effecting the immune system as well as the tumor; and PH-804 that targets the TIGIT, a protein which inhibits the activity of Natural Killer cells. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

Xenetic Biosciences

NASDAQ:XBIO

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial